S C Mehta1, D R Lu. 1. Department of Pharmaceutics, College of Pharmacy, University of Georgia, Athens 30602, USA.
Abstract
PURPOSE: Boron neutron capture therapy (BNCT) is a form of radiochemotherapy that is becoming increasingly important for the treatment of malignant gliomas, malignant melanomas and other forms of cancer. Targeted delivery of boron to tumors is a critical prerequisite for successful BNCT. METHODS: Strategies that involve synthetic chemical approaches and biochemical and biophysical approaches are employed to meet this requirement. Compounds developed for targeting to tumors include borocaptate sodium (BSH) and p-boronophenylalanine (BPA) which are currently in clinical use. RESULTS: Boronated porphyrins, nucleosides, nucleotides and other boronated compounds show potentials as targeting molecules. Conjugation of boron compounds to macromolecules such as monoclonal antibodies, epidermal growth factor and dextran is also employed for active or passive tumor targeting. CONCLUSIONS: Boron delivery via microparticulate carriers such as liposomes, high density lipoproteins and microcapsules is also attractive for its potential application in BNCT.
PURPOSE:Boron neutron capture therapy (BNCT) is a form of radiochemotherapy that is becoming increasingly important for the treatment of malignant gliomas, malignant melanomas and other forms of cancer. Targeted delivery of boron to tumors is a critical prerequisite for successful BNCT. METHODS: Strategies that involve synthetic chemical approaches and biochemical and biophysical approaches are employed to meet this requirement. Compounds developed for targeting to tumors include borocaptate sodium (BSH) and p-boronophenylalanine (BPA) which are currently in clinical use. RESULTS:Boronated porphyrins, nucleosides, nucleotides and other boronated compounds show potentials as targeting molecules. Conjugation of boron compounds to macromolecules such as monoclonal antibodies, epidermal growth factor and dextran is also employed for active or passive tumor targeting. CONCLUSIONS:Boron delivery via microparticulate carriers such as liposomes, high density lipoproteins and microcapsules is also attractive for its potential application in BNCT.
Authors: Y Mishima; C Honda; M Ichihashi; H Obara; J Hiratsuka; H Fukuda; H Karashima; T Kobayashi; K Kanda; K Yoshino Journal: Lancet Date: 1989-08-12 Impact factor: 79.321
Authors: J S Hill; S B Kahl; A H Kaye; S S Stylli; M S Koo; M F Gonzales; N J Vardaxis; C I Johnson Journal: Proc Natl Acad Sci U S A Date: 1992-03-01 Impact factor: 11.205
Authors: K Shelly; D A Feakes; M F Hawthorne; P G Schmidt; T A Krisch; W F Bauer Journal: Proc Natl Acad Sci U S A Date: 1992-10-01 Impact factor: 11.205
Authors: Y Akine; N Tokita; K Tokuuye; M Satoh; Y Fukumori; H Tokumitsu; R Kanamori; T Kobayashi; K Kanda Journal: J Cancer Res Clin Oncol Date: 1992 Impact factor: 4.553
Authors: H Yanagië; T Tomita; H Kobayashi; Y Fujii; T Takahashi; K Hasumi; H Nariuchi; M Sekiguchi Journal: Br J Cancer Date: 1991-04 Impact factor: 7.640
Authors: Casey Moore; Brenda I Hernández-Santiago; Selwyn J Hurwitz; Chalet Tan; Chris Wang; Raymond F Schinazi Journal: J Neurooncol Date: 2005-09 Impact factor: 4.130
Authors: Jennifer J Sudimack; Dianne Adams; Joan Rotaru; Supriya Shukla; Junhua Yan; Masaru Sekido; Rolf F Barth; Werner Tjarks; Robert J Lee Journal: Pharm Res Date: 2002-10 Impact factor: 4.200
Authors: José Vedelago; Marcelo Romero; Facundo Mattea; Sebastián Triviño; María Del Mar Montesinos; Walter Keil; Mauro Valente Journal: Sci Rep Date: 2021-06-10 Impact factor: 4.379